Results 141 to 150 of about 24,935 (185)

Mitigating IAPA mortality in the ICU: is it time for personalized immunotherapy? [PDF]

Crit Care
Yang S, Zhang L, Zhang C, Liu L, Cao J.
europepmc   +1 more source

Modeling viral shedding and symptom outcomes in oseltamivir-treated experimental influenza infection. [PDF]

PLoS One
Fujita Y, Akao M, Tatematsu D, Iwami S, Nakamura N, Iwanami S.   +5 more
europepmc   +1 more source

Prognostic factors in H7N9 avian influenza: a systematic review based on case reports. [PDF]

BMC Infect Dis
Li F, Song K, Ren X.
europepmc   +1 more source

Association Between Oseltamivir Timing and Clinical Outcomes in Hospitalized Children with Influenza: A Retrospective Cohort Study. [PDF]

Pediatric Health Med Ther
Albohassan HS, Jradi N, Al Jabri A, AlThani H, Ibrahim M, Alomran MA.   +5 more
europepmc   +1 more source

H1N1 seasonal surge in India, 2026: Emerging public health threat and evidence based preventive strategies. [PDF]

New Microbes New Infect
Choudhary OP, Choudhary P.
europepmc   +1 more source

Prompt and Intensive Antiviral Chemoprophylaxis in Nursing Home Influenza Outbreaks.

JAMA Intern Med
Silva JBB, Hsieh HT, Howe CJ, Gravenstein S, Reich LA, Zullo AR.   +5 more
europepmc   +1 more source

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers [PDF]

British Journal of Clinical Pharmacology, 2016
The aims of this study were to compare the pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese individuals and to determine the effect of obesity on the pharmacokinetic properties of oseltamivir and the active antiviral ...
Podjanee Jittamala, Nicholas White, Warunee Hanpithakpong   +2 more
exaly   +2 more sources